Thursday, April 24

Registration and Networking Breakfast
7:30-9:00 AM | W190 and W194

Welcome
9:00-9:15 AM

Spotlight Session 1: Bristol Myers Squibb
9:15-10:00 AM

• Introduction
• Michael Pourdehnad – Senior Vice President, Head of Early Clinical Development, Hematology, Oncology and Cell Therapy
• Q&A

Break
10:00-10:15 AM | W196 Foyer

Spotlight Session 2: Pfizer
10:15-11:00 AM

• Introduction
• Megan O'Meara – Interim Chief Development Officer and Head of Early Stage Development, Pfizer Oncology‍
• Discussion / Q&A

Break
11:00-11:15 AM | W196 Foyer

Spotlight Session 3: Johnson & Johnson Innovative Medicine
11:15 AM-12:00 PM

• Introduction
• Yusri A. Elsayed – Senior Vice President, Head of Oncology R&D
• Discussion / Q&A

Networking Lunch
12:00-1:30 PM | W190 and W194

Panel Discussion A
12:15-1:15 PM

• Next Generation Bispecifics | Moderator: Andrew Berens and Daina Graybosch - Leerink Partners | Panelists: Craig Gibbs, AsherBio; Jeff Infante, Johnson & Johnson Innovative Medicine; Bill Lundberg, Merus

Spotlight Session 4: Bayer Pharmaceuticals
1:30-2:15 PM

• Introduction
• Dominik Ruettinger – Global Head Research and Early Development Oncology
• Discussion / Q&A

Break
2:15-2:30 PM | W196 Foyer

Spotlight Session 5: AstraZeneca
2:30-3:15 PM

• Introduction
• Susan M. Galbraith – Executive Vice-President, Oncology Research & Development
• Discussion / Q&A

Break
3:15-3:30 PM | W196 Foyer

Spotlight Session 6: Eli Lilly & Company
3:30-4:15 PM

• Introduction
• Arjun Balar – Senior Vice President, Global Clinical Development
• Discussion / Q&A

Break
4:15-4:30 PM | W196 Foyer

Showcase Session 1
4:30-5:30 PM

• Introduction
• Crossbow Therapeutics - Briggs Morrison - Chief Executive Officer
• Aethon Therapeutics - Sean Toenjes - Executive Director of Chemistry & Innovation
• Zymeworks - Lucas Donigian - Vice President, Business & Commercial Development
• Discussion / Q&A

Concurrent Panel Discussion B-C
5:45-6:45 PM

• Drugging the Undruggable / Transcription Factors | Moderator: Jonathan Chang, Leerink Partners | Panelists: Liron Bar-Peled, Massachusetts General Hospital; NickGlover, MycRX; Rami Rahal, MPM BioImpact; Peter Smith, Remix Therapeutics

‍

Reception
7:00-9:00 PM | Regency Ballroom, Hyatt Regency McCormick Place

‍

‍Friday, April 25

Registration and Networking Breakfast
7:00-8:00 AM | W190 and W194

Spotlight Session 7: Novartis
8:00-8:45 AM

• Introduction
• Dushen Chetty – Global Head of Oncology, Development
• Discussion / Q&A

Break
8:45-9:00 AM

Spotlight Session 8: Genentech/Roche
9:00-9:45 AM

• Introduction
• Levi A. Garraway – Executive Vice President, Head of Product Development, and Chief Medical Officer
• Discussion / Q&A

Break
9:45-10:00 AM

Spotlight Session 9: Merck
10:00-10:45 AM

• Introduction
• Jane A. Healy – Vice President and Head of Oncology Early Development
• Discussion / Q&A

Break
10:45-11:00 AM

Spotlight Session 10: Gilead
11:00-11:45 AM

• Introduction
• Flavius Martin – Executive Vice President
• Discussion / Q&A

Break
11:45-12:00 AM

Spotlight Session 11: Amgen
12:00-12:45 PM

• Introduction
• Jean-Charles Soria – Senior Vice President of Oncology
• Erin Denny – Executive Director, External R&D, Inflammation, Oncology
• Discussion / Q&A

Closing Keynote / Fireside Chat
12:45-1:45 PM

Closing Remarks
1:45-2:00 PM

Lunch Available
2:00-3:00 PM | W190 and W194

‍

Thursday, April 24

Registration and Networking Breakfast
7:30-9:00 AM | W190 and W194

Showcase Session 2
4:30-5:30 PM

• Introduction
• CatenaBio - Saurabh Johri, Chief Business Officer
• Innate Pharma - JonathanDickinson, Chairman of the Executive Board, Chief Executive Officer
• OncoC4 - PanPan, Senior Vice President, Head of Business Development

Concurrent Panel Discussion B-C
5:45-6:45 PM

• T Cell Engagers | Moderators: Andrew Berens and Daina Graybosch, Leerink Partners | Panelists: Yusri A. Elsayed, Johnson & Johnson Innovative Medicine; Ken Galbraith, Zymeworks; Martin Lehr, Context Therapeutics

‍

Reception
7:00-9:00 PM | Regency Ballroom, Hyatt Regency McCormick Place

‍